Clinical Trials Advancement and Methods PIA Business Meeting Summary

Location: ExCel London (Platinum Suite 1)
Date: Saturday, July 15, 2017
Time: 9 - 10 a.m.
PIA Chair(s)/Meeting Facilitator(s): Hiroko Dodge

- **10 Attendees**
- **Upcoming elections:**
  - The PIA would like the Chair (and Co-Chair(s), if needed) to hold a 3 year term; the 3rd year will be the transition period
  - Modified bylaws will be circulated among members at the time of Fall election (when soliciting nominations). Yumeka provided a Microsoft Word template of Bylaws earlier.
- **Progress:**
  - We provided the first Clinical Trials Methods Workshop this year as pre-conference workshop: 61 registrants for the Workshop
  - Membership grew over 600 (second largest following Imaging Core)
  - 3rd year to provide the PIA scientific symposium at PIA day, AAIC (PIA day symposium successfully completed (see below for the full schedule*))
- **2017-2018 Goals:**
  - Fall Elections
  - Organize another method pre-conference workshop (2018 AAIC at Chicago)
  - Revitalize working group activities (the elected new chair will contact working group leaders to facilitate symposium abstracts submission to AAIC—early Spring, after the election).
  - Establish new working groups at 2018 AAIC
  - Increase membership
- **Action Items:**
  - Yumeka will distribute a Call for Nominations email to the PIA membership
  - PIA Chairs will create a shortlist of nominations
  - Provide the Executive Committee the workshop results in August

*PIA day schedule:
NEW PERSPECTIVES IN AD CLINICAL TRIAL APPROACHES

- Opening remarks, Hiroko Dodge (Oregon Health & Science University and University of Michigan) 7:32- 7:35
- Howard Feldman (University of California San Diego): Re-approaching proof of concept: emerging opportunities 7:35 – 7:52
• Michael Lutz (Duke University): Application of molecular understanding of AD to clinical development: lessons from cancer research 7:52 – 8:09
• Todd Golde (University of Florida): Disruptive approaches to development and testing of new AD therapies 8:09 – 8:26
• Lon S Schneider (Keck School of Medicine of USC): Phase 3 trials have failed because their phase 2 trials were uninformative: The need to learn some stuff 8:26 – 8:43

UPDATES ON INTERNATIONAL CONSORTIUM AND INTRODUCTION OF NEW INITIATIVES

• Craig Ritchie (University of Edinburgh): What’s new and exciting from the European Prevention of Alzheimer’s Dementia Consortium (EPAD) 8:45 – 8:55
• Kaarin Anstey (the Australian National University): Introduction of IRNDP Initiative 8:55-9:00

Minutes taken by: April Ross and Ari Buhaumick